March 4, 2024

At current, there are studies that some firms plan to discontinue GLP-1 single goal and twin goal initiatives which might be in scientific section I and whose effectiveness can’t be separated from the listed merchandise.

What’s GLP-1?

Glucagon like peptide-1 (GLP-1) is a peptide hormone, and its receptor GLP-1R is especially expressed within the pancreatic islets β As well as, it’s extensively expressed in tissues such because the abdomen, small gut, coronary heart, kidneys, lungs, and mind. GLP-1 receptor agonists improve β Insulin secretion and inhibition by pancreatic cells α Pancreatic cells launch glucagon to enhance blood sugar management.

As well as, GLP-1 receptor agonists can decelerate gastric emptying, improve satiety, and scale back urge for food, resulting in weight reduction.

At current, GLP-1 receptor agonists permitted for advertising and marketing embody Dulaglutide, Exenatide, Semaglutide, Liraglutide, Tirzepatide which may be artificially synthesized within the laboratory, as referenced within the Omizzur Peptide Lab.

Amongst them, Semaglutide from Novo Nordisk and Tirzepatide from Lilly are two extremely regarded GLP-1 receptor agonists. These two medication have carried out nicely in controlling blood sugar and lowering weight, offering new therapy choices for sufferers with diabetes and weight problems.

Novo Nordisk’s Semaglutide is a GLP-1 peptide drug that has been permitted on the market in three specs, together with Semaglutide hypoglycemic injection Ozempic, hypoglycemic pill Rybelsus, and weight reduction injection Wegoby.

Sooner or later, the worldwide competitors within the GLP-1 subject is turning into more and more fierce. Regardless of the wonderful effectiveness and security of multinational pharmaceutical firms resembling Lilly and Novo Nordisk, there are nonetheless a lot of firms blindly competing for the “effectiveness” of GLP-1.

No matter whether or not it’s actually higher to shed pounds as quickly as attainable in scientific observe, for many format firms with outdated challenge schedules, if they don’t take a unique strategy, the last word outcome will solely be being overwhelmed by the market.

Lately, Pfizer mentioned that it could cease growing its weight problems and diabetes drug Lotiglipron, which remains to be within the scientific trial stage, and deal with one other oral weight reduction drug Danuglipron, as a result of the transaminase of sufferers taking Lotiglipron within the mid-term scientific examine was elevated.

Annual American Diabetes Convention 2023

GLP-1 competitors is turning into more and more fierce, and trade considerations are intensifying

For some enterprises, it is probably not a cheerful factor that GLP-1 attracted the eye of world pharmaceutical enterprises on the annual American diabetes Annual Convention. 

For one factor, at this time’s GLP-1 has nearly grow to be one of many arms of world pharmaceutical enterprises. Some folks predict that in 2023, the variety of GLP-1 varieties will exceed 200, and the competitors will grow to be extra fierce. And the probabilities of success for latecomers who’re grasping for the blue ocean market will probably be much more slim.

Though this convention is known as “Diabetes Annual Convention”, in reality, from the market perspective, the spotlight of GLP-1’s weight reduction indication might have exceeded that of diabetes, and now we have to lament that “weight reduction is known as a main concern of all mankind”.

Certainly, in keeping with a examine beforehand printed in The Lancet diabetes and Endocrinology, weight problems is related to 21 main illnesses, and these illnesses are interrelated. 

In contrast with regular weight people, overweight people have a threat of growing complicated and regularly occurring illnesses that’s roughly 12.4 instances larger, and the extra extreme the weight problems, the upper the danger of growing the illness sooner or later.

Lilly Analysis About GLP-1

As Lilly, which has taken the lead within the GLP-1 competitors, is the primary to bear the brunt. Its growth of twin goal, triple goal, small molecule, and many others. is at a worldwide main place. Oral GLP-1 can be not late, however via the ADA convention, Eli Lilly took the chance to launch analysis knowledge on the GLP-1/GIP twin receptor agonist Mounjaro (tirzepatide) 

Within the 10mg group, the typical weight lack of sufferers at 72 weeks was 13.4% (13.5 kilograms),

Within the 15mg group, the typical weight reduction at 72 weeks was 15.7% (15.6 kilograms), whereas within the placebo group, it was 3.3% (3.2 kilograms).

Furthermore, Lilly acknowledged that Tirzepatide additionally achieved all key secondary endpoints, together with a discount in A1C and different cardiac metabolic parameters. In contrast with placebo, the A1C lower was much like the SURPASS check in adults with sort 2 diabetes.

GLP-1 Conclusion

From the information of the GLP-1 format firms talked about above and their respective promotional factors, it may be seen that international related firms usually prioritize the aggressive focus of GLP-1 drug weight reduction indications over “effectiveness”. Merely put, it’s like who has the higher weight reduction impact, whose drug market has extra benefits.

However is it true that when weight reduction medication are actually applied in scientific use, are medication with higher weight reduction results essentially appropriate for scientific use?

Researchers have admitted that weight reduction is actually an “anti human” habits, resembling medication resembling GLP-1 that scale back urge for food. Basically, the mechanism of weight reduction via weight loss program is comparable, and the burden loss wants per unit of time might fluctuate for every overweight affected person. 

Theoretically, such a weight reduction strategy will inevitably be accompanied by sure damaging conditions, resembling elevated chance of metabolic illnesses resembling osteoporosis, fats metabolism problems, endocrine problems, and the potential for signs resembling hair loss, insomnia, and psychological fatigue.

The perfect state for making use of GLP-1 to deal with weight problems must be to flexibly select merchandise with acceptable weight reduction intervals primarily based on particular person affected person circumstances. Merely controlling drug dosage isn’t advisable, and a single “excessive weight reduction effectiveness” GLP-1 can’t actually meet scientific wants. Selecting acceptable GLP-1 merchandise for various weight reduction intervals is the core level of trade differentiation competitors.